Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery
Launched by HOSPITAL FOR SPECIAL SURGERY, NEW YORK · May 18, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of acupuncture to help patients recover more quickly after total hip replacement (THR) surgery. The goal is to see if adding acupuncture during surgery can reduce the need for opioid pain medications and shorten the time patients spend in the hospital. By testing this approach, researchers hope to create a better recovery plan that combines multiple methods to improve patient outcomes.
To participate in this study, you need to be between 18 and 80 years old, be scheduled for a total hip replacement, and be able to follow the study guidelines. You should also be in good health (ASA status of 1 or 2) and speak English. However, if you have been using opioids for a long time, have certain medical conditions, or have specific issues with your ears, you may not be eligible. If you join the trial, you can expect to receive acupuncture during your surgery, which is a safe and low-cost treatment that may help you recover more effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA status of 1 or 2
- • Ages 18-80
- • Undergoing a total hip replacement
- • Ability to follow study protocol
- • English-speaking
- Exclusion Criteria:
- • Non-English speaking
- • Chronic opioids use (6 weeks or more)
- • Contraindication to neuraxial anesthesia or peripheral nerve block
- • Intending to receive general anesthesia
- • Contraindication to intra-op protocol
- • Implanted cardiac device (i.e. pacemaker)
- • Active ear infection
- • Non-native ear, previous scarring or surgery
- • Ear gauges or other deforming ear piercing
- • Allergy to Nickel
About Hospital For Special Surgery, New York
The Hospital for Special Surgery (HSS) in New York is a world-renowned institution specializing in orthopedic surgery, rheumatology, and rehabilitation. Recognized for its commitment to advancing medical research and improving patient outcomes, HSS serves as a leading clinical trial sponsor, facilitating innovative studies that explore cutting-edge treatments and therapies. With a team of expert clinicians and researchers, HSS aims to enhance clinical practices through rigorous scientific inquiry, ultimately contributing to the advancement of musculoskeletal health and patient care on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Stephanie Cheng, MD
Principal Investigator
Hospital for Special Surgery, New York
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials